Analyst Price Target is $10.00
▲ +147.52% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Eton Pharmaceuticals in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 147.52% upside from the last price of $4.04.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Eton Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.